Business
Oruka Therapeutics Announces New Board Member and Board Transition
Appoints accomplished commercial leader Chris Martin to its Board of Directors MENLO PARK, Calif., Dec. 11, 2025 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc.
About this update from Oruka Therapeutics, Inc.
[{"type":"text","content":"Appoints accomplished commercial leader Chris Martin to its Board of Directors\nMENLO PARK, Calif., Dec. 11, 2025 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. (“Oruka”) (Nasdaq: ORKA), a clinical-stage biotechnology company developing novel biologics designed to set a new standard for the treatment of chronic skin diseases including plaque psoriasis (PsO), today announced the appointment of Chris Martin to its Board of Directors. Additionally, Cameron Turtle, DPhil, resigned from the Board effective December 11, 2025. “As we rapidly advance our co-lead programs through development, I’m pleased to announce this board transition at Oruka,” said Lawrence Klein, PhD, Chief Executive Officer of Oruka Therapeutics. “Chris’s expertise can bring tremendous value to the company as we advance towards late-stage development and think more concretely about how ORKA-001 and -002 could enter the market. We have greatly valued Cameron’s contributions on our Board in helping to shape our strategy and direction in the early stages of building our company, and I would like to personally thank him on behalf of our Board for his service.” Mr. Martin has over 25 years of commercial expertise spanning sales, marketing, market access, commercial operations, and business development. Most recently he served as Chief Commercial Officer of Verona Pharma, which was acquired by Merck in October 2025 for approximately $10B. At Verona he was responsible for building the commercial organization and launch strategy for Ohtuvayreâ (ensifentrine), which has seen rapid commercial uptake for the maintenance treatment of COPD. Prior to Verona, he held a variety of commercial roles of increasing responsibility at SK Life Science, Melinta Therapeutics, and Salix Pharmaceuticals, which included leading multiple successful product launches and contributing to other corporate acquisitions. Mr. Martin received a Bachelor of Science in Financial Management from Clemson University. About Oruka Therapeutics Oruka Therapeutics is developing novel biologics designed to set a new standard for the treatment of chronic skin diseases. Oruka’s mission is to offer patients suffering from chronic skin diseases like plaque psoriasis the greatest possible freedom from their condition by achieving high rates of complete disease clearance with dosing as infrequently as once or twice a y...